# BIIB catalysts: BIOGEN INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/biib/catalysts

> BIOGEN INC. (BIIB) has 31 upcoming catalysts. The next is the litifilimab topline data readout, Dec 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, year only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | BIOGEN INC. |
| Ticker | BIIB (Nasdaq) |
| SEC CIK | 875045 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/biib |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 27, 2016 | [Zinbryta (daclizumab) FDA approval](https://sec-api.dev/pdufa/daclizumab) | BIIB |  | completed, approved | "BLA761029 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20160527, review_priority STANDARD; sponsor_name BIOGEN; product ZINBRYTA (DACLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761029%22)) |
| December 23, 2016 | [SPINRAZA (nusinersen) FDA approval](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, approved | "NDA209531 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20161223, review_priority PRIORITY; sponsor_name BIOGEN; product SPINRAZA (NUSINERSEN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209531%22)) |
| October 29, 2019 | [Vumerity (diroximel fumarate) FDA approval](https://sec-api.dev/pdufa/diroximel) | BIIB |  | completed, approved | "NDA211855 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20191029, review_priority STANDARD; sponsor_name BIOGEN; product VUMERITY (DIROXIMEL FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211855%22)) |
| February 5, 2020 | [Tecfidera (dimethyl fumarate) label expansion decision](https://sec-api.dev/pdufa/dimethyl) | BIIB |  | completed, approved | "NDA204063 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20200205, review_priority STANDARD; sponsor_name BIOGEN; product TECFIDERA (DIMETHYL FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204063%22)) |
| March 27, 2020 | [Avonex (interferon beta-1a) label expansion decision](https://sec-api.dev/pdufa/interferon-beta-1a) | BIIB |  | completed, approved | "BLA103628 SUPPL-5263 (Efficacy): submission_status AP, submission_status_date 20200327, review_priority STANDARD; sponsor_name BIOGEN; product AVONEX (INTERFERON BETA-1A)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA103628%22)) |
| March 27, 2020 | [Plegridy (peginterferon beta-1a) label expansion decision](https://sec-api.dev/pdufa/peginterferon-beta-1a) | BIIB |  | completed, approved | "BLA125499 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20200327, review_priority STANDARD; sponsor_name BIOGEN IDEC INC; product PLEGRIDY (PEGINTERFERON BETA-1A)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125499%22)) |
| June 16, 2020 | [SPINRAZA (nusinersen) label expansion decision](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, approved | "NDA209531 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20200616, review_priority STANDARD; sponsor_name BIOGEN; product SPINRAZA (NUSINERSEN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209531%22)) |
| January 29, 2021 | [Plegridy (peginterferon beta-1a) label expansion decision](https://sec-api.dev/pdufa/peginterferon-beta-1a) | BIIB |  | completed, approved | "BLA125499 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20210129, review_priority STANDARD; sponsor_name BIOGEN IDEC INC; product PLEGRIDY (PEGINTERFERON BETA-1A)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125499%22)) |
| June 7, 2021 | [Aduhelm (aducanumab-avwa) FDA approval](https://sec-api.dev/pdufa/aducanumab-avwa) | BIIB |  | completed, approved | "BLA761178 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210607, review_priority PRIORITY; sponsor_name BIOGEN INC; product ADUHELM (ADUCANUMAB-AVWA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761178%22)) |
| Dec 2022 | [LUNSUMIO (lunsumio) FDA approval](https://sec-api.dev/pdufa/lunsumio) | BIIB | relapsed or refractory follicular lymphoma | completed, approved | "In addition, we receive low-single digit royalties on sales of LUNSUMIO outside the U.S. In December 2022 LUNSUMIO was granted accelerated approval by the FDA for the treatment of relapsed or refractory follicular lymphoma." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/875045/000087504525000009/biib-20241231.htm)) |
| February 8, 2023 | [Aduhelm (aducanumab-avwa) label expansion decision](https://sec-api.dev/pdufa/aducanumab-avwa) | BIIB |  | completed, approved | "BLA761178 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20230208, review_priority STANDARD; sponsor_name BIOGEN INC; product ADUHELM (ADUCANUMAB-AVWA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761178%22)) |
| February 10, 2023 | [Tecfidera (dimethyl fumarate) label expansion decision](https://sec-api.dev/pdufa/dimethyl) | BIIB |  | completed, approved | "NDA204063 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20230210, review_priority STANDARD; sponsor_name BIOGEN; product TECFIDERA (DIMETHYL FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204063%22)) |
| February 10, 2023 | [Vumerity (diroximel fumarate) label expansion decision](https://sec-api.dev/pdufa/diroximel) | BIIB |  | completed, approved | "NDA211855 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20230210, review_priority STANDARD; sponsor_name BIOGEN; product VUMERITY (DIROXIMEL FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211855%22)) |
| February 28, 2023 | [SKYCLARYS® (omaveloxolone) FDA approval](https://sec-api.dev/pdufa/omaveloxolone) | BIIB | To treat Friedrich’s ataxia | completed, approved | "Skyclarys \| omaveloxolone \| 2/28/2023 \| To treat Friedrich’s ataxiaDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| April 25, 2023 | [QALSODY (tofersen) FDA approval](https://sec-api.dev/pdufa/tofersen) | BIIB | To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation | completed, approved | "Qalsody \| tofersen \| 4/25/2023 \| To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutationDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| August 4, 2023 | [Zurzuvae (zuranolone) FDA approval](https://sec-api.dev/pdufa/zuranolone) | BIIB | To treat postpartum depression Press Release | completed, approved | "Zurzuvae \| zuranolone \| 8/4/2023 \| To treat postpartum depression Press ReleaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| Sep 2023 | [SKYCLARYS® (omaveloxolone) FDA approval](https://sec-api.dev/pdufa/omaveloxolone) | BIIB |  | completed, approved | "As part of our acquisition of Reata in September 2023 we obtained a rare pediatric disease PRV in connection with the approval of SKYCLARYS, which was approved by the FDA in February 2023." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm)) |
| September 29, 2023 | [Tofidence (tocilizumab-bavi) FDA approval](https://sec-api.dev/pdufa/tocilizumab-bavi) | BIIB |  | completed, approved | "BLA761354 ORIG-1: submission_status AP, submission_status_date 20230929, review_priority STANDARD; sponsor_name BIOGEN MA; product TOFIDENCE (TOCILIZUMAB-BAVI)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761354%22)) |
| Sep 2024 | [SPINRAZA (nusinersen) topline data readout](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, positive | "•In September 2024 we announced positive topline data from the Phase 2/3 DEVOTE study of nusinersen, which evaluated the safety and efficacy of a higher dose regimen of nusinersen in treatment-naive symptomatic infants with SMA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/875045/000087504525000009/biib-20241231.htm)) |
| Sep 2024 | [Dapirolizumab pegol topline data readout](https://sec-api.dev/pdufa/dapirolizumab-pegol) | BIIB | moderate-to-severe SLE | completed, positive | "In September 2024 we and UCB announced positive topline data from the Phase 3 PHOENYCS GO study of dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in people living with moderate-to-severe SLE." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/875045/000087504525000009/biib-20241231.htm)) |
| December 20, 2024 | [SKYCLARYS® (omaveloxolone) label expansion decision](https://sec-api.dev/pdufa/omaveloxolone) | BIIB |  | completed, approved | "NDA216718 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20241220, review_priority STANDARD; sponsor_name BIOGEN US; product SKYCLARYS (OMAVELOXOLONE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216718%22)) |
| 2025 | [Felzartamab trial start](https://sec-api.dev/pdufa/felzartamab) | BIIB |  | scheduled | "•Felzartamab Phase 3 study initiated in late antibody-mediated rejection in kidney transplant patients with plans to initiate Phase 3 trials of felzartamab in IgA nephropathy and primary membranous nephropathy in 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000014/exhibit991-q12025pressrele.htm)) |
| February 12, 2025 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen Inc. (NASDAQ: BIIB) today reported fourth quarter and full year 2024 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000004/exhibit991-q42024pressrele.htm)) |
| March 31, 2025 | [Felzartamab trial start](https://sec-api.dev/pdufa/felzartamab) | BIIB |  | completed | "During the first quarter of 2025 we accrued a milestone payment due to MorphoSys of $35.0 million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the three months ended March 31, 2025, and paid in April 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504526000045/biib-20260331.htm)) |
| May 1, 2025 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen reports strong first quarter 2025 results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000014/exhibit991-q12025pressrele.htm)) |
| Jun 2025 | [Salanersen topline data readout](https://sec-api.dev/pdufa/salanersen) | BIIB |  | completed, positive | "•In June 2025 we announced positive topline results from the Phase 1b study of salanersen, an ASO being developed for the treatment of SMA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504525000049/biib-20250930.htm)) |
| Jun 2025 | [Salanersen interim data readout](https://sec-api.dev/pdufa/salanersen) | BIIB |  | completed, positive | "•In June 2025 we announced positive interim topline results from the Phase 1b study of salanersen, an ASO being developed for the treatment of SMA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm)) |
| June 30, 2025 | [Felzartamab trial start](https://sec-api.dev/pdufa/felzartamab) | BIIB | IgAN | completed | "During the first quarter of 2025 we accrued a milestone payment due to MorphoSys of $35.0 million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the six months ended June 30, 2025, and subsequently paid in April 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504525000033/biib-20250630.htm)) |
| July 8, 2025 | [Tecfidera (dimethyl fumarate) primary completion](https://sec-api.dev/pdufa/dimethyl) | BIIB | Relapsing-Remitting Multiple Sclerosis | completed | "NCT02283853 (Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-08 (ACTUAL); Lead Sponsor Biogen; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02283853)) |
| July 31, 2025 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen reports strong second quarter 2025 results and increases full year 2025 guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000035/exhibit991-q22025pressrele.htm)) |
| August 31, 2025 | [LEQEMBI (lecanemab) PDUFA date](https://sec-api.dev/pdufa/lecanemab) | BIIB |  | scheduled | "•In January 2025 the FDA accepted for review the BLA for LEQEMBI subcutaneous autoinjector for weekly maintenance dosing, with a PDUFA action date set for August 31, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504525000033/biib-20250630.htm)) |
| September 22, 2025 | [SPINRAZA (nusinersen) PDUFA date](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, complete response letter | "•Nusinersen (SPINRAZA) higher dose regimen for SMA filings accepted by FDA and EMA; FDA PDUFA of September 22, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000004/exhibit991-q42024pressrele.htm)) |
| September 22, 2025 | [SPINRAZA (nusinersen) complete response letter (CRL)](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA209531_20250922.pdf%22)) |
| September 30, 2025 | [Felzartamab trial start](https://sec-api.dev/pdufa/felzartamab) | BIIB | IgAN | completed | "During the first quarter of 2025 we accrued a milestone payment due to MorphoSys of $35.0 million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the nine months ended September 30, 2025, and paid in April 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504525000049/biib-20250930.htm)) |
| October 30, 2025 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen reports strong third quarter 2025 results and updates full year 2025 guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/exhibit991-q32025pressrele.htm)) |
| December 31, 2025 | [Felzartamab trial start](https://sec-api.dev/pdufa/felzartamab) | BIIB | AMR and IgAN, respectively | completed | "During 2025 we made milestone payments to MorphoSys of $35.0 million and $30.0 million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR and IgAN, respectively, which were recognized in acquired in-process research and development, upfront and milestone expense within our consolidated statements of income for the year ended December 31, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/875045/000087504526000013/biib-20251231.htm)) |
| February 6, 2026 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen Inc. (Nasdaq: BIIB) today reported fourth quarter and full year 2025 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504526000011/exhibit991-q42025pressrele.htm)) |
| February 10, 2026 | [BIIB091 primary completion](https://sec-api.dev/pdufa/biib091) | BIIB | Relapsing Forms of Multiple Sclerosis | completed | "NCT05798520 (A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-10 (ACTUAL); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05798520)) |
| March 9, 2026 | [Biib122 225 mg primary completion](https://sec-api.dev/pdufa/biib122) | BIIB | Parkinson Disease | completed | "NCT05348785 (A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-09 (ACTUAL); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05348785)) |
| March 11, 2026 | [Diranersen primary completion](https://sec-api.dev/pdufa/diranersen) | BIIB | Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer's Disease Dementia | completed | "NCT05399888 (A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-11 (ACTUAL); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05399888)) |
| March 27, 2026 | [SPINRAZA (nusinersen) label expansion decision](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, approved | "NDA209531 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20260327, review_priority STANDARD; sponsor_name BIOGEN; product SPINRAZA (NUSINERSEN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209531%22)) |
| mid-2026 | [Biib122 225 mg topline data readout](https://sec-api.dev/pdufa/biib122) | BIIB |  | scheduled | "A clinical data readout of the global Phase 2b LUMA study of BIIB122 for early-stage Parkinson's disease is expected in mid-2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000062/ex991pressreleaseq12026.htm)) |
| April 3, 2026 | [SPINRAZA (nusinersen) PDUFA date](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, approved | "•Today announced that high dose nusinersen (SPINRAZA) in SMA was successfully resubmitted with the FDA with an updated PDUFA date of April 3, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504525000047/exhibit991-q32025pressrele.htm)) |
| April 29, 2026 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen reports strong first quarter 2026 results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504526000042/exhibit991-q12026pressrele.htm)) |
| May 2026 | [Biib122 225 mg topline data readout](https://sec-api.dev/pdufa/biib122) | BIIB |  | completed, missed | "In May 2026 Biogen and Denali announced topline results from the Phase 2b LUMA study evaluating BIIB122, which showed that BIIB122 did not meet its primary and secondary endpoints." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260930.htm)) |
| May 19, 2026 | [Tecfidera (dimethyl fumarate) topline data readout](https://sec-api.dev/pdufa/dimethyl) | BIIB | Relapsing-Remitting Multiple Sclerosis | completed | "NCT02283853 (Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-08 (ACTUAL); Lead Sponsor Biogen; Results First Posted 2026-05-19." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02283853?tab=results)) |
| May 24, 2026 | [LEQEMBI (lecanemab) PDUFA date](https://sec-api.dev/pdufa/lecanemab) | BIIB |  | delayed | "•In January 2026 the FDA accepted for review the supplemental BLA for LEQEMBI subcutaneous autoinjector, LEQEMBI IQLIK, for a weekly starting dose, with a PDUFA action date of May 24, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504526000045/biib-20260331.htm)) |
| Jul 2026 | [LEQEMBI (lecanemab) FDA approval](https://sec-api.dev/pdufa/lecanemab) | BIIB |  | completed, approved | "For example, we recently sought, and in July 2026 the FDA approved, of a subcutaneous formulation of LEQEMBI as a starting dose in the U.S. Our ability to realize the anticipated benefits from the subcutaneous formulation of LEQEMBI depends on among other things, the successful commercial launch of the subcutaneous formulation and patient and physician adoption." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260930.htm)) |
| Jul 2026 | [LEQEMBI (lecanemab) PDUFA date](https://sec-api.dev/pdufa/lecanemab) | BIIB |  | scheduled | "•In May 2026 the FDA extended the review period by three months for the supplemental BLA for LEQEMBI subcutaneous autoinjector, LEQEMBI IQLIK, for a weekly initiation dose, with a new PDUFA action date of August 24, 2026; in July 2026 the FDA approved the supplemental BLA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/875045/000087504526000075/biib-20260630.htm)) |
| July 29, 2026 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen reports strong second quarter 2026 results demonstrating progress toward its goal of sustainable revenue growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504526000073/exhibit991-q22026pressrele.htm)) |
| July 30, 2026 | [SPINRAZA (nusinersen) primary completion](https://sec-api.dev/pdufa/nusinersen) | BIIB | Muscular Atrophy, Spinal | completed | "NCT04729907 (A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-30 (ACTUAL); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04729907)) |
| September 2026 | [Litifilimab primary completion](https://sec-api.dev/pdufa/litifilimab) | BIIB | Lupus Erythematosus, Systemic | delayed | "NCT04961567 (A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-27 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04961567)) |
| September 2026 | [Litifilimab primary completion](https://sec-api.dev/pdufa/litifilimab) | BIIB | Lupus Erythematosus, Systemic | delayed | "NCT04895241 (A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-30 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895241)) |
| October 2026 | [Litifilimab primary completion](https://sec-api.dev/pdufa/litifilimab) | BIIB | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | delayed | "NCT05531565 (A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-10-20 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05531565)) |
| October 28, 2026 | [BIOGEN INC. earnings report](https://sec-api.dev/companies/biib/catalysts) | BIIB |  | completed | "Biogen Reports Third Quarter 2026 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504526000094/exhibit991-q32026pressrele.htm)) |
| Dec 2026 | [Litifilimab topline data readout](https://sec-api.dev/pdufa/litifilimab) | BIIB | Lupus Erythematosus, Systemic | scheduled | "•The Company expects to announce top line data from both TOPAZ-1 and TOPAZ-2 Phase 3 studies, evaluating litifilimab in SLE, in the first half of December 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504526000094/exhibit991-q32026pressrele.htm)) |
| December 2026 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Antibody-mediated Rejection | scheduled | "NCT06685757 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06685757)) |
| Dec 2026 to Mar 2027 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Antibody-mediated Rejection | scheduled | "NCT06685757 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06685757)) |
| May to Aug 2027 | [Biib017 (peginterferon beta-1a) topline data readout](https://sec-api.dev/pdufa/biib017-peginterferon-beta-1a) | BIIB | Multiple Sclerosis, Relapsing-Remitting | scheduled | "NCT03958877 (A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-20 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03958877)) |
| May to Aug 2027 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT06935357 (A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06935357)) |
| May 2027 | [Biib017 (peginterferon beta-1a) primary completion](https://sec-api.dev/pdufa/biib017-peginterferon-beta-1a) | BIIB | Multiple Sclerosis, Relapsing-Remitting | scheduled | "NCT03958877 (A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-20 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03958877)) |
| May 2027 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT06935357 (A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06935357)) |
| Aug to Nov 2027 | [QALSODY (tofersen) topline data readout](https://sec-api.dev/pdufa/tofersen) | BIIB | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | scheduled | "NCT04856982 (Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-07 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04856982)) |
| August 2027 | [QALSODY (tofersen) primary completion](https://sec-api.dev/pdufa/tofersen) | BIIB | Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | scheduled | "NCT04856982 (Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-07 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04856982)) |
| Sep to Dec 2027 | [SPINRAZA (nusinersen) topline data readout](https://sec-api.dev/pdufa/nusinersen) | BIIB | Spinal Muscular Atrophy | scheduled | "NCT05067790 (A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05067790)) |
| September 2027 | [SPINRAZA (nusinersen) primary completion](https://sec-api.dev/pdufa/nusinersen) | BIIB | Spinal Muscular Atrophy | scheduled | "NCT05067790 (A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05067790)) |
| Nov 2027 to Feb 2028 | [SKYCLARYS® (omaveloxolone) topline data readout](https://sec-api.dev/pdufa/omaveloxolone) | BIIB | Friedreich Ataxia | scheduled | "NCT06953583 (A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06953583)) |
| November 2027 | [SKYCLARYS® (omaveloxolone) primary completion](https://sec-api.dev/pdufa/omaveloxolone) | BIIB | Friedreich Ataxia | scheduled | "NCT06953583 (A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-11-16 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06953583)) |
| Jan to Apr 2028 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Graves' Disease | scheduled | "NCT07722546 (A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-31 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07722546)) |
| January 2028 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Graves' Disease | scheduled | "NCT07722546 (A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01-31 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07722546)) |
| Feb to May 2028 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Microvascular Inflammation | scheduled | "NCT07219043 (A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-10 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219043)) |
| February 2028 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Microvascular Inflammation | scheduled | "NCT07219043 (A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-10 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219043)) |
| Jun to Sep 2028 | [Salanersen topline data readout](https://sec-api.dev/pdufa/salanersen) | BIIB | Spinal Muscular Atrophy | scheduled | "NCT07444476 (A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-23 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07444476)) |
| June 2028 | [Salanersen primary completion](https://sec-api.dev/pdufa/salanersen) | BIIB | Spinal Muscular Atrophy | scheduled | "NCT07444476 (A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-23 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07444476)) |
| Aug to Nov 2028 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Immunoglobulin A Nephropathy | scheduled | "NCT07889362 (A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-08-13 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07889362)) |
| August 2028 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Immunoglobulin A Nephropathy | scheduled | "NCT07889362 (A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-08-13 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07889362)) |
| Sep to Dec 2028 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Generalized Myasthenia Gravis | scheduled | "NCT07939802 (A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07939802)) |
| September 2028 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Generalized Myasthenia Gravis | scheduled | "NCT07939802 (A Study to Learn About the Effects of Felzartamab on Daily Living Activities and Its Safety in Adults With Generalized Myasthenia Gravis (gMG) Ages 18 to 80 Years Old): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07939802)) |
| Nov 2028 to Feb 2029 | [Salanersen topline data readout](https://sec-api.dev/pdufa/salanersen) | BIIB | Muscular Atrophy, Spinal | scheduled | "NCT07221669 (A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-28 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221669)) |
| November 2028 | [Salanersen primary completion](https://sec-api.dev/pdufa/salanersen) | BIIB | Muscular Atrophy, Spinal | scheduled | "NCT07221669 (A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-28 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221669)) |
| Jun to Sep 2029 | [Biib059 (litifilimab) topline data readout](https://sec-api.dev/pdufa/biib059-litifilimab) | BIIB | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | scheduled | "NCT06044337 (A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-06-26 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06044337)) |
| June 2029 | [Biib059 (litifilimab) primary completion](https://sec-api.dev/pdufa/biib059-litifilimab) | BIIB | Subacute Cutaneous Lupus Erythematosus; Chronic Cutaneous Lupus Erythematosus | scheduled | "NCT06044337 (A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2029-06-26 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06044337)) |
| Jul to Oct 2029 | [Salanersen topline data readout](https://sec-api.dev/pdufa/salanersen) | BIIB | Muscular Atrophy, Spinal | scheduled | "NCT07444450 (A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-27 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07444450)) |
| July 2029 | [Salanersen primary completion](https://sec-api.dev/pdufa/salanersen) | BIIB | Muscular Atrophy, Spinal | scheduled | "NCT07444450 (A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-27 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07444450)) |
| Jan to Apr 2030 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Primary Membranous Nephropathy | scheduled | "NCT06962800 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-28 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06962800)) |
| January 2030 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Primary Membranous Nephropathy | scheduled | "NCT06962800 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-28 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06962800)) |

## Drugs

- [Aduhelm (aducanumab-avwa)](https://sec-api.dev/pdufa/aducanumab-avwa): 
- [Biib017 (peginterferon beta-1a)](https://sec-api.dev/pdufa/biib017-peginterferon-beta-1a): Multiple Sclerosis, Relapsing-Remitting
- [Biib059 (litifilimab)](https://sec-api.dev/pdufa/biib059-litifilimab): Subacute Cutaneous Lupus Erythematosus
- [BIIB091](https://sec-api.dev/pdufa/biib091): Relapsing Forms of Multiple Sclerosis
- [Biib122 225 mg](https://sec-api.dev/pdufa/biib122): Parkinson Disease
- [Zinbryta (daclizumab)](https://sec-api.dev/pdufa/daclizumab): 
- [Dapirolizumab pegol](https://sec-api.dev/pdufa/dapirolizumab-pegol): moderate-to-severe sle
- [Tecfidera (dimethyl fumarate)](https://sec-api.dev/pdufa/dimethyl): Relapsing-Remitting Multiple Sclerosis
- [Diranersen](https://sec-api.dev/pdufa/diranersen): Mild Cognitive Impairment Due to Alzheimer's Disease
- [Vumerity (diroximel fumarate)](https://sec-api.dev/pdufa/diroximel): 
- [Felzartamab](https://sec-api.dev/pdufa/felzartamab): igan, amr and igan, respectively, igan, as well, Generalized Myasthenia Gravis, Immunoglobulin A Nephropathy, Immunoglobulin A Nephropathy (IgAN), Microvascular Inflammation, Graves' Disease
- [Avonex (interferon beta-1a)](https://sec-api.dev/pdufa/interferon-beta-1a): 
- [LEQEMBI (lecanemab)](https://sec-api.dev/pdufa/lecanemab): 
- [Litifilimab](https://sec-api.dev/pdufa/litifilimab): Subacute Cutaneous Lupus Erythematosus, Lupus Erythematosus, Systemic
- [LUNSUMIO (lunsumio)](https://sec-api.dev/pdufa/lunsumio): relapsed or refractory follicular lymphoma
- [SPINRAZA (nusinersen)](https://sec-api.dev/pdufa/nusinersen): Muscular Atrophy, Spinal, Spinal Muscular Atrophy
- [SKYCLARYS® (omaveloxolone)](https://sec-api.dev/pdufa/omaveloxolone): children and adults living with fa, To treat Friedrich’s ataxia, Friedreich Ataxia
- [Plegridy (peginterferon beta-1a)](https://sec-api.dev/pdufa/peginterferon-beta-1a): 
- [Salanersen](https://sec-api.dev/pdufa/salanersen): Spinal Muscular Atrophy, Muscular Atrophy, Spinal
- [Tofidence (tocilizumab-bavi)](https://sec-api.dev/pdufa/tocilizumab-bavi): 
- [QALSODY (tofersen)](https://sec-api.dev/pdufa/tofersen): To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation, Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
- [Zurzuvae (zuranolone)](https://sec-api.dev/pdufa/zuranolone): To treat postpartum depression Press Release

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/biib/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "BIIB catalysts: BIOGEN INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/biib/catalysts

```bibtex
@misc{secapidev_companies_biib_catalysts_20261116,
  title        = {BIIB catalysts: BIOGEN INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/biib/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_biib_catalysts_20261116","title":"BIIB catalysts: BIOGEN INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/biib/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
